EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE

3596 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE:

# Side effect Count
0 BONE DENSITY DECREASED 1605
1 CHRONIC KIDNEY DISEASE 874
2 TOOTH LOSS 822
3 OSTEOPOROSIS 758
4 BONE LOSS 748
5 OSTEONECROSIS 713
6 PAIN 711
7 EMOTIONAL DISTRESS 692
8 MULTIPLE FRACTURES 691
9 RENAL FAILURE 650
See all common reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE

EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BONE DEMINERALISATION 84 0.0793
1 MAXILLOFACIAL OPERATION 5 0.0575
2 BONE DENSITY DECREASED 1605 0.0512
3 BONE LOSS 748 0.0497
4 SKELETAL INJURY 462 0.0446
5 MULTIPLE FRACTURES 691 0.0420
6 TOOTH LOSS 822 0.0396
7 OSTEOPENIA 539 0.0355
8 BONE DENSITY ABNORMAL 103 0.0275
9 LIMB FRACTURE 4 0.0267
See all enriched reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE